Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The BioPharma Shares Rising On Omicron Hopes And Fears

Room For New Options In Vaccines And Antibodies

Executive Summary

Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.

You may also be interested in...



Finance Watch: Public Market Opens Up Enough To Let An IPO Through

Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.

Still A COVID-19 Game Changer? UK’s Cautious Launch Of MSD’s Antiviral Lagevrio

The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.

COVID-19 Vaccine Makers Pledge Rapid Response To Omicron Threat

While news of a potentially highly transmissible new variant is causing alarm, Pfizer/BioNTech and Moderna are already pursuing a multi-pronged response to B.1.1.529.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel